---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-139445"
form_type: "8-K"
ticker: "CTKB"
cik: "0001831915"
company_name: "Cytek Biosciences, Inc."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T09:53:10.382047+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cytek Q1 revenue $37.1M (+6% YoY); net loss widens to $6.8M; organic revenue -4%; revises FY23 outlook to $205-220M

## Summary
- Total revenue $37.1M, up 6% YoY; constant-currency revenue $38.1M (+9%).
- Organic revenue (ex-Luminex) $33.7M, down 4% YoY; U.S. pharma/biotech weakness cited.
- Net loss $6.8M vs $2.2M loss in Q1 2022; adjusted EBITDA -$2.5M vs +$1.9M.
- Completed Luminex flow cytometry asset acquisition for $44.9M on Feb 28, 2023; contributed $3.4M revenue.
- Revised FY2023 revenue guidance to $205-220M (25-34% growth), citing macro uncertainties and longer sales cycles.

## SEC filing metadata
- accession: 0001193125-23-139445
- form_type: 8-K
- ticker: CTKB
- cik: 0001831915
- company_name: Cytek Biosciences, Inc.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831915/000119312523139445/0001193125-23-139445-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831915/000119312523139445/d468414d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-139445
- JSON: https://secwatch.observer/filing/0001193125-23-139445.json
- Plain text: https://secwatch.observer/filing/0001193125-23-139445.txt

## Key facts
- Earnings Releases
  Cytek Biosciences, Inc. reported the first quarter ended March 31, 2023 results: revenue $37.1 million, net income $6.8 million.
  - Period: the first quarter ended March 31, 2023
  - Revenue: $37.1 million
  - Net income: $6.8 million
  - Result: reported results
  source text: First Quarter Highlights • Total revenue was $37.1 million, or $38.1 million on a constant currency basis, representing 6% and 9% increases respectively, over the first quarter of 2022. • Organic revenue for Cytek’s existing product portfolio was $33.7 million in the first quarter of 2023, representing a decline of 4% compared to the first quarter of 2022 • Revenue from the product lines acquired from Luminex Corporation, which closed February 28, 2023, was $3.4 million • Net loss was $6.8 million and adjusted EBITDA was $(2.5) million for the first quarter of 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831915/000119312523139445/0001193125-23-139445-index.htm
- Earnings Releases
  Cytek Biosciences, Inc. reported full year 2023 results: revenue $205 million to $220 million. Guidance lowered.
  - Period: full year 2023
  - Revenue: $205 million to $220 million
  - Guidance: lowered
  - Result: guidance update
  source text: As a result of macro-economic uncertainties causing longer sales cycles, Cytek Biosciences has revised its full year 2023 revenue outlook and now expects total revenue to be in the range of $205 million to $220 million, representing growth of 25% to 34% over full year 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831915/000119312523139445/0001193125-23-139445-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.